Bupi Heavy0.5%+8%

Bupi Heavy is a hyperbaric ("heavy") local anesthetic solution indicated for producing subarachnoid block (spinal anesthesia) in adults undergoing surgical procedures. The dextrose component increases the specific gravity of the solution above that of cerebrospinal fluid, allowing the anesthesia provider to control the spread of the block within the subarachnoid space by positioning the patient.

• Established/FDA-approved use: Spinal (subarachnoid) anesthesia for lower extremity and perineal surgical procedures, lower abdominal surgical procedures, and vaginal delivery.
• Established/FDA-approved use: Spinal anesthesia for cesarean section, when administered by personnel experienced in obstetric anesthesia.

Bupi Heavy is intended for use only by, or under the direct supervision of, clinicians experienced in the techniques of spinal anesthesia, with resuscitation equipment and drugs immediately available.

Each mL of Bupivacaine Hydrochloride + Dextrose injection typically contains bupivacaine hydrochloride (commonly 5 mg/mL, equivalent to 0.5% w/v) and dextrose (commonly 80 mg/mL, 8% w/v) in water for injection, formulated as a sterile, preservative-free, hyperbaric solution for single-dose subarachnoid (spinal) injection. Strength and exact composition may vary by manufacturer and pack size; always confirm against the product label being dispensed.

Bupi Heavy is a sterile, hyperbaric (dextrose-containing) solution of bupivacaine, an amide-type local anesthetic, formulated specifically for spinal (intrathecal/subarachnoid) administration. Because the added dextrose makes the solution denser than cerebrospinal fluid, it is described as a "heavy" spinal anesthetic solution; after injection into the subarachnoid space it tends to settle with gravity, so the anesthetist can influence the level of the block by adjusting patient position immediately after injection.

Bupi Heavy is supplied in single-dose, preservative-free ampoules or vials and is administered only by lumbar puncture technique by trained anesthesia personnel.

Bupi Heavy belongs to the amide-type local anesthetic class, specifically formulated as a hyperbaric solution for spinal anesthesia.

Bupivacaine Hydrochloride + Dextrose acts by reversibly blocking voltage-gated sodium channels in nerve cell membranes, which prevents the generation and conduction of nerve impulses. This blocks sensory, motor, and autonomic (sympathetic) nerve transmission in the region exposed to the drug, producing loss of sensation and often muscle relaxation below the level of the spinal block.

The dextrose in Bupivacaine Hydrochloride + Dextrose raises the specific gravity of the solution above that of cerebrospinal fluid (hyperbaric solution), so the drug spreads preferentially to dependent areas of the subarachnoid space according to patient position, allowing more predictable and controllable segmental spread of anesthesia compared with plain (isobaric) bupivacaine.

Onset of sensory block typically occurs within minutes of intrathecal injection, with block duration of approximately 1.5 to 3 hours or more depending on dose, patient factors, and the addition of adjuncts (e.g., epinephrine) where used.

Bupi Heavy is administered exclusively by lumbar subarachnoid (spinal) injection performed by qualified anesthesia personnel using strict aseptic technique. It must NOT be given by intravenous, epidural, intramuscular, or any other route. Patient positioning immediately after injection (e.g., supine, lateral, or sitting, and use of head-up/head-down tilt) is used to control the cephalad spread of the hyperbaric solution and achieve the desired block level. Resuscitation equipment, oxygen, and emergency drugs must be immediately available whenever Bupi Heavy is administered.

Clinically significant interactions with Bupi Heavy include:

• Other local anesthetics or agents structurally related to amide-type local anesthetics: concurrent or repeated use increases the risk of additive systemic (cardiac and CNS) toxicity; cumulative doses of all local anesthetics used must be considered.
• CNS depressants (e.g., opioids, sedatives, general anesthetics): may produce additive central nervous system and respiratory depression when used with Bupi Heavy-induced spinal anesthesia.
• Antihypertensive agents and vasodilators: spinal anesthesia with Bupi Heavy itself causes sympathetic blockade and hypotension; concurrent antihypertensives or vasodilators can produce additive, sometimes severe, hypotension requiring careful monitoring and vasopressor support.
• Drugs associated with methemoglobinemia (e.g., nitrates/nitrites, certain sulfonamides, some antimalarials): concurrent use may increase the risk of clinically significant methemoglobinemia.

Adverse effects of Bupi Heavy are largely related to the physiological effects of spinal anesthesia (sympathetic blockade) and, rarely, to systemic absorption or inadvertent intravascular exposure.

• Very common: Hypotension (due to sympathetic nerve blockade), bradycardia.
• Common: Nausea and vomiting (usually secondary to hypotension), urinary retention, post-dural puncture (spinal) headache, backache at the injection site, shivering.
• Less common/serious: High or total spinal block with respiratory insufficiency or apnea, diaphragmatic paralysis, severe/prolonged hypotension, cardiac arrhythmias including bradyarrhythmias progressing to cardiac arrest.
• Rare but serious: Local anesthetic systemic toxicity (LAST) presenting as circumoral numbness, tinnitus, dizziness, tremors, seizures, and cardiovascular collapse, typically from inadvertent intravascular injection; allergic/anaphylactic reactions; neurological complications such as persistent paresthesia, arachnoiditis, or cauda equina syndrome (very rare); methemoglobinemia.

Bupi Heavy is used for spinal anesthesia during labor, vaginal delivery, and cesarean section under the direct supervision of an obstetric anesthesia specialist; it should be used in pregnancy only when the anesthesia is clinically necessary for the procedure, as determined by the treating physician. Local anesthetics readily cross the placenta; fetal/neonatal bradycardia and other effects have been reported, and maternal hypotension from the sympathetic block must be promptly corrected (e.g., left lateral uterine displacement, intravenous fluids, vasopressors) to maintain uteroplacental perfusion.

Bupivacaine is excreted in small amounts in breast milk. Bupi Heavy should be used in nursing mothers only if clearly needed and under specialist supervision, weighing the anesthetic benefit against any potential risk to the infant; consult a physician for individual guidance.

Bupi Heavy is for spinal (intrathecal) administration ONLY, by or under the direct supervision of clinicians experienced in spinal anesthesia techniques, in a facility equipped with immediately available resuscitation equipment, oxygen, and emergency drugs, because of the risk of high or total spinal block, severe hypotension, bradycardia, respiratory depression/apnea, and cardiovascular collapse.

• Continuous monitoring of blood pressure, heart rate, oxygenation, and level of sensory/motor block is required throughout and after administration.
• Use with caution and reduced dosing in elderly, debilitated, acutely ill, hypovolemic, or cardiovascular-compromised patients, and in pregnant patients, who may be more susceptible to hypotension and high block.
• Aspirate before and during injection to avoid inadvertent intravascular or intrathecal overdose.
• Avoid use in patients with pre-existing severe hypotension, hypovolemia, or uncorrected coagulopathy (see Contraindications).
• Inadvertent intravascular injection can cause local anesthetic systemic toxicity (LAST); resuscitative equipment including lipid emulsion should be available where required by local protocol.
• This is a single-dose, preservative-free product for a single patient; discard any unused portion.

Overdose or excessive intrathecal/intravascular exposure to Bupi Heavy is a medical emergency. Signs may include a high or total spinal block with severe hypotension, bradycardia, difficulty breathing or apnea from respiratory muscle paralysis, and, with systemic toxicity, circumoral numbness, tinnitus, restlessness, tremors, seizures, cardiac arrhythmias, and cardiovascular collapse.

Any suspected overdose or these symptoms require immediate medical attention: securing the airway with 100% oxygen and ventilatory support, prompt treatment of hypotension and bradycardia with intravenous fluids and vasopressors, anticonvulsant therapy for seizures, and full cardiopulmonary resuscitation with advanced cardiac life support if cardiac arrest occurs. Because Bupi Heavy is administered only in monitored clinical settings, management must be carried out immediately by the attending anesthesia/medical team; there is no home treatment for overdose.

Store at room temperature, 20-25°C (68-77°F); protect from light and freezing. Use single-dose ampoules/vials for one patient on one occasion only and discard any unused portion, as Bupi Heavy contains no preservative. Do not use if the solution is discolored or contains particulate matter. Keep out of reach of children and store as directed on the product label.

Elderly patients: May require reduced doses of Bupi Heavy and are at greater risk of pronounced hypotension and higher-than-expected block levels; careful titration and monitoring are advised.

Renal/hepatic impairment: No formal dose adjustment guidelines are established; bupivacaine is metabolized hepatically, so patients with significant hepatic impairment may be at increased risk of systemic toxicity if inadvertent intravascular exposure occurs, and should be monitored closely.

Cardiovascular disease: Patients with pre-existing cardiac conduction disturbances or severe cardiovascular disease require extra caution, as sympathetic blockade from spinal anesthesia can cause pronounced hypotension and bradycardia.

See Pediatric Uses and Pregnancy and Lactation sections for those populations.

Bupi Heavy is administered as a single intraoperative injection for spinal anesthesia; it is not a chronic or repeat-dosed medication. The duration of anesthetic effect is typically 1.5 to 3 hours or longer depending on dose and individual factors, and is determined and monitored by the anesthesia provider for the duration of the surgical procedure and immediate recovery period.

Bupivacaine Hydrochloride + Dextrose belongs to the amide-type local anesthetic class, formulated as a hyperbaric (dextrose-containing) spinal anesthetic solution.

Bupivacaine Hydrochloride + Dextrose works by reversibly binding to and blocking voltage-gated sodium channels on nerve fibers, preventing sodium influx that is required to generate and propagate nerve action potentials. This interrupts sensory, motor, and sympathetic nerve conduction in the spinal nerve roots exposed to the drug within the cerebrospinal fluid, producing anesthesia and often muscle relaxation in the corresponding dermatomes. The dextrose component makes the solution hyperbaric relative to cerebrospinal fluid, allowing gravity-dependent control of the block's cephalad spread through patient positioning.

C

The safety and efficacy of Bupi Heavy for spinal anesthesia have not been established in patients younger than 18 years of age. Administration in this age group is not recommended based on current product labeling, and pediatric spinal anesthesia with this product should only be considered by a specialist pediatric anesthesiologist in exceptional circumstances where no suitable alternative exists.